Amylyx Pharmaceuticals
AMLX
179 hedge funds and large institutions have $1.36B invested in Amylyx Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 71 increasing their positions, 44 reducing their positions, and 28 closing their positions.
429% more call options, than puts
Call options by funds: $6.39M | Put options by funds: $1.21M
61% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 44
43% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 28
6% more funds holding
Funds holding: 169 → 179 (+10)
9% less capital invested
Capital invested by funds: $1.49B → $1.36B (-$135M)
20.81% less ownership
Funds ownership: 123.05% → 102.24% (-21%)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.8M |
| 2 |
Janus Henderson Group
London,
|
+$26.2M |
| 3 |
BlackRock
New York
|
+$26M |
| 4 |
CC
Commodore Capital
New York
|
+$21.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$54.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$33.3M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$25.8M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$16.2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$11.7M |
AMLX Hedge Fund Activity: Q4 2025 in Review
179 of the 8,263 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q4 2025, worth a combined $1.36B — down 9% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new AMLX positions and 28 closed out — a net gain of 12 holders — while 71 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $69.8M. The largest seller was Adage Capital Partners, cutting an estimated $54.9M.
- 179 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q4 2025, up from 169 in Q3 2025.
- Funds reported $1.36B of Amylyx Pharmaceuticals stock for Q4 2025, down 9% quarter-over-quarter.
- 40 funds opened new Amylyx Pharmaceuticals positions in Q4 2025 and 28 closed out, a net change of +12 holders.
- The largest Amylyx Pharmaceuticals buyer in Q4 2025 was Fidelity Investments, an estimated $69.8M added.
- The largest Amylyx Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $54.9M sold.
Based on aggregated 13F filings for Q4 2025.